Associated Papers
Genomic landscape of hormone therapy-resistant HR-positive, HER2-negative breast cancer.
Chaubal R et al.
Breast Cancer Research and Treatment, 2025
40652157 (PubMed )
Supplement: 10549_2025_7759_MOESM1_ESM.xlsx › stable6
Frequent FOXA1-Activating Mutations in Extramammary Paget's Disease.
Takeichi T et al.
Cancers, 2020
32235312 (PubMed )
Supplement: cancers-12-00820-s001.pdf
Deep analysis of acquired resistance to FGFR1 inhibitor identifies MET and AKT activation and an expansion of AKT1 mutant cells.
Gimenez-Xavier P et al.
Oncotarget, 2018
30140389 (PubMed )
Supplement: oncotarget-09-31549-s003.xlsx › Sheet1
Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target.
Dufva O et al.
Nature Communications, 2018
29674644 (PubMed )
Supplement: 41467_2018_3987_MOESM6_ESM.xlsx › NKTCL_L16
Select a paper to view details